ArticleWorld journal of gastrointestinal surgery2024
Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis.
Article in World journal of gastrointestinal surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- D-dimer predicts the response of patients with gastric cancer to first-line immunotherapy combined with chemotherapy.Journal of gastrointestinal oncology · 2025Article
- Therapeutic efficacy of immunotherapy for gastric cancer metastasis.World journal of gastrointestinal surgery · 2024Article
- Pembrolizumab in patients with gastric cancer and liver metastases: A paradigm shift in immunotherapy.World journal of gastrointestinal surgery · 2024Article
- Role of immunotherapy in gastric cancer with liver metastasis.World journal of clinical oncology · 2024Article
- Impact of liver metastasis on immunotherapy in gastric carcinoma.World journal of gastrointestinal surgery · 2024Article
- Gastric cancer liver metastasis will reduce the efficacy of immunotherapy.World journal of gastrointestinal surgery · 2024Article
- Immunotherapy for gastric cancer and liver metastasis: Is it time to bid farewell.World journal of gastrointestinal surgery · 2024Article
- Consideration on immunotherapy of liver metastases of malignant tumors.World journal of gastrointestinal surgery · 2024Article
- Treatment strategy and therapy based on immune response in patients with gastric cancers.World journal of gastrointestinal surgery · 2024Article
- Impact of immunotherapy on liver metastasis.World journal of gastrointestinal surgery · 2024Article
- Immunotherapy in gastric cancer with liver metastasis: Challenges and opportunities.World journal of gastrointestinal surgery · 2024Article
- Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer-Narrative Review.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is the fifth most common type of cancer and has the fourth highest death rate among all cancers. There is a lack of studies examining the impact of liver metastases on the effectiveness of immunotherapy in individuals diagnosed with GC.
aimTo investigate the influence of liver metastases on the effectiveness and safety of immunotherapy in patients with advanced GC.
methodsThis retrospective investigation collected clinical data of patients with advanced stomach cancer who had immunotherapy at our hospital from February 2021 to January 2023. The baseline attributes were compared using either the Chi-square test or the Fisher exact probability method. The chi-square test and Kaplan-Meier survival analysis were employed to assess the therapeutic efficacy and survival duration in GC patients with and without liver metastases.
resultsThe analysis comprised 48 patients diagnosed with advanced GC, who were categorized into two groups: A liver metastasis cohort (
conclusionImmunotherapy is less effective in GC patients with liver metastases compared to those without liver metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.